Diagnostics (Aug 2022)

Cancer Stem Cell Markers in Rhabdomyosarcoma in Children

  • Joanna Radzikowska,
  • Anna M. Czarnecka,
  • Teresa Klepacka,
  • Magdalena Rychłowska-Pruszyńska,
  • Anna Raciborska,
  • Bożenna Dembowska-Bagińska,
  • Maciej Pronicki,
  • Andrzej Kukwa,
  • Wojciech Fendler,
  • Urszula Smyczyńska,
  • Wojciech Kukwa,
  • Antoni Krzeski

DOI
https://doi.org/10.3390/diagnostics12081895
Journal volume & issue
Vol. 12, no. 8
p. 1895

Abstract

Read online

(1) Background: The aim of the present study was to assess the cancer stem cell (CSC) markers CD24, CD44, CD133, and ALDH1A1 in rhabdomyosarcoma (RMS) in children and to define their prognostic role in this group of patients. (2) Methods: The study material was archival tissue specimens collected from 49 patients under 18 years of age and who had been diagnosed with RMS. Immunohistochemistry (IHC) was used to evaluate the expression of the selected CSC markers in the tumor tissue. Expression was evaluated using a semiquantitative IRS scale based on the one developed by Remmele and Stenger and was correlated with the clinical and pathomorphological parameters of prognostic importance in RMS. (3) Results: Expression of the selected CSC markers CD24, CD44, CD133, and ALDH1A1 was demonstrated in 83.7%, 55.1%, 81.6%, and 100% of the RMS patients, respectively. The expression of all of the assessed CSC markers was statistically significantly higher in the study group versus the control group. No significant correlation was found between the expression of the selected CSC markers and clinical and pathological prognostic factors that were analyzed. The expression of the CSC markers did not have a significant influence on RMS survival rates. (4) Conclusions: The results of the conducted study confirm the expression of selected CSC markers in rhabdomyosarcoma tissue in children. The study did not support the prognostic relevance of the expression of any of the assessed CSC markers. However, further studies are needed to fully understand the relevance of the selected CSC markers in RMS carcinogenesis.

Keywords